The Optimal Health Manifesto
6 min read ·

Is Pinealon actually better than 5-Amino-1MQ

By Rick Gold

Is Pinealon actually BETTER than 5-Amino-1MQ? Wrong question, and I'll tell you why in a second. Short answer: no, because they're not fighting for the same job. Pinealon works your brain. 5-Amino-1MQ works your fat cells and your NAD pool. Comparing them head-to-head is like asking whether a smoke detector beats a fire extinguisher.

Both of these get lumped into "longevity peptides" because they showed up in the same forum threads around the same time, sold by the same handful of vendors, chased by the same crowd of people optimizing everything. That's it. That's basically the only thing they share. So let's stop pretending this is a fair fight and actually look at what each one does. I've spent way too many damn hours in the Khavinson-group literature to skip this step.

What They're Actually Built To Do

Pinealon is a tiny three-amino-acid peptide (Glu-Asp-Arg, if you're keeping score) built by Russian researchers to act on brain tissue. It's genuinely oral, which is rare for a peptide, and it's proposed to work through a handful of mechanisms at once: helping it cross into brain cells, nudging gene expression in neurons, and calming oxidative stress in the cortex. In a dish, using amyloid-stressed mouse hippocampal neurons, EDR restored dendritic "mushroom spine" density back up near control levels. Mushroom spines are the little structures where your brain physically stores long-term memory. That's a rebuild story, not just a symptom-cover story.

5-Amino-1MQ isn't even a peptide. It's a small molecule, and its whole job is to block one enzyme: NNMT. NNMT sits in your NAD salvage pathway and methylates a usable NAD precursor into a form your body just pees out. Block NNMT and less of that precursor gets wasted. It doesn't hand you new NAD. It plugs a leak in the tank you already have. That's a car-running-out-of-gas problem, not a make-more-gas solution, and if you don't already have fuel in the tank, plugging the leak does NOTHING for you.

See the mismatch? One's a brain compound trying to protect memory circuits. The other's a metabolic compound trying to stop a specific enzyme from draining a fuel pathway. Nope. These two were NEVER in the same weight class.

The Evidence, Honestly

Here's where I have to be straight with you, because this is the part vendors gloss over.

Pinealon's whole evidence base comes from the Khavinson group and their collaborators in Russia. Decades of it. Real publication record, not a fly-by-night thing. There's one small human cohort, 32 patients, that reported an anabolic effect and slower biological-aging markers. There's the mushroom-spine rescue study above. There's mouse work in Alzheimer's models. What there ISN'T: a single Western randomized controlled trial. Zero. None have been run.

5-Amino-1MQ's evidence base is thinner in a different way. The mechanism, blocking NNMT, is textbook, well-established biochemistry. But the actual pharmacokinetic data on the molecule itself comes from one rat study. One. And human data? There isn't any. Not a trial, not a published case series, nothing. Every dose anyone runs is extrapolated from rodent numbers and community experience.

So who wins the evidence fight? Honestly, it's close, and it's close in a way that should make you skeptical of BOTH, not confident in either. Pinealon has more total research volume and an actual, if small, human cohort. 5-Amino-1MQ has cleaner, more textbook biochemistry but almost nothing measured in the compound itself beyond that one animal PK paper. Frankly, neither one has what I'd call a slam dunk. That's not me being a downer, that's just where the science actually sits right now.

Cost And Side-Effect Load

Pinealon runs pretty light on side effects. Some folks get a headache the first few days. Dose it at night and you might mess with your sleep, so mornings only. Mild GI upset on the oral route sometimes. The bigger practical risk isn't the peptide itself, it's fake product. This whole Khavinson-tripeptide category gets counterfeited hard, so a verified COA (a lab report proving what's actually in the vial) matters WAY more here than almost anywhere else in the peptide world. You bet it does.

5-Amino-1MQ's side-effect profile is light too, mild GI stuff, take it with food and you're mostly fine. But there's a REAL safety wrinkle worth knowing: if you inhibit NNMT without enough NAD substrate on board, and your CD38 (another NAD-draining enzyme) is running high, the NAD you do salvage can preferentially feed CD38-high cells, including senescent and tumor cells. No reason to panic. It's a reason to never run it standalone. Stack it with an actual NAD source and you're fine.

And since I'm about to tell you where to actually get these, full disclosure first: Heads up, OHM has an affiliate relationship with the vendors linked here, so we earn a commission if you buy through one of these links. It costs you nothing extra and it does not change which peptide the evidence supports. Pinealon runs through BioLongevity with code OHM-15. 5-Amino-1MQ runs through US Pure Peptides with code OHM20.

Dosing, And Who Each One Actually Suits

Now the part my lawyer makes me say, and honestly he's right:

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

For Pinealon, the Russian clinical protocols run oral doses way lower than a lot of vendor marketing suggests. My editorial read: start around 200 mcg a day, oral, on an empty stomach, for 20 to 30 days, then take a break. A handful of independent self-trackers, completely unrelated to each other, have separately reported noticeably better sleep on it too, which is a fun bonus nobody was marketing it for.

For 5-Amino-1MQ, the standard oral tier most people land on is 50 to 100 mg a day, run for 60 days, then off for at least 30 while your enzyme system resets.

So who's each one actually for? If you're chasing brain fog, cognitive aging, or memory support, and you've already got sleep and stress under control, Pinealon is the one worth reading up on. If you're carrying real metabolic weight, running NAD+ already, and want to stop losing precursor to a leaky enzyme, 5-Amino-1MQ earns its spot in that stack. If you're lean, metabolically healthy, and just chasing a 'more NAD' headline, save your money and put it toward NAD+ itself instead, there's NO leak worth plugging yet.

"Better" was always the wrong frame. These two aren't competing. They're doing completely different jobs for completely different problems, and picking the right one starts with picking the right problem.

Thanks for reading! In health, Rick Gold

Frequently asked questions

Is Pinealon better than 5-Amino-1MQ for brain health?

For brain health specifically, yes, because 5-Amino-1MQ was never built to touch cognition. Pinealon is a Khavinson-group tripeptide aimed at brain cortex and hippocampal tissue, with mechanism-level data on memory-related dendritic structures. 5-Amino-1MQ works on a metabolic enzyme (NNMT) tied to your NAD pathway and body composition, with no direct cognitive mechanism at all.

Can you take Pinealon and 5-Amino-1MQ together?

There's no known interaction because they work on completely different systems, one on brain tissue, one on a metabolic enzyme. Some people run both inside a broader longevity stack for that reason. As always, run 5-Amino-1MQ alongside real NAD+ substrate rather than standalone, and check any personal contraindications with your prescribing physician first.

Which one has better human evidence, Pinealon or 5-Amino-1MQ?

Pinealon has the edge on paper. It has a small published human cohort study plus a decade-plus Russian research record, while 5-Amino-1MQ has zero published human data of any kind. Neither has a Western randomized controlled trial, so 'better evidence' here means 'less thin,' not 'proven.'

Is 5-Amino-1MQ safe to take without NAD+?

It's not recommended as a standalone protocol. Blocking NNMT without enough NAD substrate on board, especially alongside elevated CD38 activity, can shunt the NAD you do salvage toward CD38-high cells, including senescent and tumor cells. Pair it with an actual NAD source and the risk profile changes substantially.